MCID: END040
MIFTS: 53

Endogenous Depression

Categories: Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endogenous Depression

MalaCards integrated aliases for Endogenous Depression:

Name: Endogenous Depression 11 14 71 75
Unipolar Depression 11 14 71
Clinical Depression 11 53 71
Depressive Disorder 43 71

Classifications:



External Ids:

Disease Ontology 11 DOID:1595
MeSH 43 D003866
SNOMED-CT 68 191599006
UMLS 71 C0011573 C0011581 C0041696 more

Summaries for Endogenous Depression

Disease Ontology: 11 A mental depression that is characterized by a dysregulation of the endogenous opioid system and not of the monaminergic system.

MalaCards based summary: Endogenous Depression, also known as unipolar depression, is related to major depressive disorder and diarrhea, and has symptoms including depressed - symptom An important gene associated with Endogenous Depression is TRH (Thyrotropin Releasing Hormone), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Parathyroid hormone and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cortex, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: 75 Endogenous depression (melancholia) is an atypical sub-class of major depressive disorder (clinical... more...

Related Diseases for Endogenous Depression

Diseases related to Endogenous Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 872)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 31.0 TTC9B TRH TPH1 SLC6A4 POMC OXT
2 diarrhea 30.9 TPH1 SLC6A4 IL6 HTR1A BDNF
3 schizoaffective disorder 30.9 SLC6A4 HTR2A HTR1A COMT BDNF
4 postpartum depression 30.8 TTC9B SLC6A4 POMC OXTR OXT NR3C1
5 movement disease 30.7 HTR2A HTR1A H2AC18 COMT BDNF
6 vascular dementia 30.7 IL6 HTR1A BDNF
7 back pain 30.7 IL6 CRP BDNF
8 conduct disorder 30.7 TPH1 SLC6A4 POMC OXTR OXT MAOA
9 hyperprolactinemia 30.6 TRH POMC HTR2A GNRH1
10 restless legs syndrome 30.6 SLC6A4 POMC MAOA COMT
11 intracranial hypertension 30.6 POMC IL6 CRP
12 parkinson disease, late-onset 30.6 TPH1 SLC6A4 MAOA HTR2A HTR1A H2AC18
13 pituitary-dependent cushing's disease 30.5 TRH POMC NR3C1 CRH
14 conn's syndrome 30.5 TRH POMC NR3C1 IL6 GNRH1 CRP
15 body dysmorphic disorder 30.5 SLC6A4 OXT MAOA HTR2A
16 somatization disorder 30.5 SLC6A4 POMC OXT IL6 CRH
17 tobacco addiction 30.5 TPH1 SLC6A4 MAOA HTR2A HTR1A H2AC18
18 antisocial personality disorder 30.5 SLC6A4 OXTR OXT MAOA HTR2A COMT
19 peptic ulcer disease 30.4 IL6 H2AC18 CRP
20 phobia, specific 30.4 SLC6A4 OXT MAOA HTR1A H2AC18 CRH
21 dissociative disorder 30.4 SLC6A4 OXT HTR2A COMT BDNF
22 amnestic disorder 30.4 OXT HTR1A BDNF
23 learning disability 30.4 H2AC18 COMT BDNF
24 paine syndrome 30.4 SLC6A4 POMC IL6 H2AC18 CRH COMT
25 toxic encephalopathy 30.4 IL6 H2AC18 BDNF
26 central diabetes insipidus 30.4 TRH POMC OXT GNRH1
27 conversion disorder 30.4 HTR2A COMT BDNF
28 congenital central hypoventilation syndrome 30.4 SLC6A4 HTR1A BDNF
29 brunner syndrome 30.4 TPH1 SLC6A4 MAOA HTR2A COMT
30 cyclothymic disorder 30.4 SLC6A4 HTR2A HTR1A COMT BDNF
31 chronic pain 30.4 COMT BDNF
32 diabetes insipidus 30.4 POMC OXTR OXT CRH
33 amenorrhea 30.3 TRH POMC OXT GNRH1 CRH
34 cannabis abuse 30.3 SLC6A4 HTR1A COMT BDNF
35 autism spectrum disorder 30.3 SLC6A4 OXTR OXT NR3C1 MAOA IL6
36 cocaine dependence 30.3 SLC6A4 POMC CRH COMT
37 craniopharyngioma 30.3 TRH IL6 GNRH1
38 premenstrual tension 30.3 POMC GNRH1
39 urinary tract infection 30.3 IL6 H2AC18 CRP
40 substance-induced psychosis 30.3 HTR2A HTR1A COMT BDNF
41 neurotic disorder 30.3 SLC6A4 POMC OXT MAOA IL6 HTR2A
42 hypoglycemia 30.3 TRH POMC OXT NR3C1 CRH BDNF
43 acne 30.3 POMC IL6 CRP CRH
44 adult syndrome 30.3 POMC NR3C1 IL6 H2AC18 CRP CRH
45 serotonin syndrome 30.3 SLC6A4 OXT MAOA HTR2A HTR1A
46 premature ovarian failure 7 30.3 POMC CRH
47 sheehan syndrome 30.2 TRH POMC CRH
48 acth deficiency, isolated 30.2 TRH POMC CRH
49 tic disorder 30.2 SLC6A4 MAOA HTR2A HTR1A COMT
50 melancholia 30.2 TRH TPH1 SLC6A4 POMC OXT MAOA

Graphical network of the top 20 diseases related to Endogenous Depression:



Diseases related to Endogenous Depression

Symptoms & Phenotypes for Endogenous Depression

UMLS symptoms related to Endogenous Depression:


depressed - symptom

GenomeRNAi Phenotypes related to Endogenous Depression according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 BDNF COMT CRH CRP EBF1 GNRH1
2 no effect GR00402-S-2 10.2 BDNF COMT CRH CRP EBF1 GNRH1

MGI Mouse Phenotypes related to Endogenous Depression:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.32 BDNF COMT CRH EBF1 GNRH1 HTR1A
2 homeostasis/metabolism MP:0005376 10.31 BDNF COMT CRH CRP GNRH1 HP1BP3
3 growth/size/body region MP:0005378 10.18 BDNF CRH EBF1 GNRH1 HP1BP3 IL6
4 endocrine/exocrine gland MP:0005379 10.13 BDNF COMT CRH GNRH1 HTR2A IL6
5 renal/urinary system MP:0005367 10.06 COMT CRH GNRH1 IL6 NR3C1 OXT
6 no phenotypic analysis MP:0003012 10.04 BDNF CRH HTR1A NR3C1 OXTR POMC
7 adipose tissue MP:0005375 9.98 CRH EBF1 IL6 NR3C1 OXT POMC
8 cardiovascular system MP:0005385 9.93 COMT CRP EBF1 HTR1A IL6 MAOA
9 digestive/alimentary MP:0005381 9.86 BDNF GNRH1 HTR2A IL6 NR3C1 OXT
10 behavior/neurological MP:0005386 9.83 BDNF COMT CRH EBF1 HTR1A HTR2A
11 integument MP:0010771 9.36 BDNF CRH EBF1 GNRH1 IL6 NR3C1

Drugs & Therapeutics for Endogenous Depression

Drugs for Endogenous Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
4
Oxcarbazepine Approved Phase 4 28721-07-5 34312
5
Scopolamine Approved, Investigational Phase 4 51-34-3 153311 3000322
6
Desipramine Approved, Investigational Phase 4 50-47-5 2995
7
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
8
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
9
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
10
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
11
Doxepin Approved, Investigational Phase 4 1668-19-5 667468 667477
12
Isocarboxazid Approved Phase 4 59-63-2 3759
13
Protriptyline Approved Phase 4 438-60-8 4976
14
Trimipramine Approved Phase 4 739-71-9 5584
15
Tranylcypromine Approved, Investigational Phase 4 155-09-9 5530 441233
16
Ziprasidone Approved Phase 4 146939-27-7 60854
17
Moclobemide Approved, Investigational Phase 4 71320-77-9 4235
18
Maprotiline Approved, Investigational Phase 4 10262-69-8 4011
19
Topiramate Approved Phase 4 97240-79-4 5284627
20
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
21
Simvastatin Approved Phase 4 79902-63-9 54454
22
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
23
Ribavirin Approved Phase 4 36791-04-5 37542
24
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
25
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
26
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
27
Calcium carbonate Approved, Investigational Phase 4 471-34-1
28
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
29
Promethazine Approved, Investigational Phase 4 60-87-7 4927
30
Nefazodone Approved, Withdrawn Phase 4 82752-99-6, 83366-66-9 4449
31
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
32
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
33
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
34
Acamprosate Approved, Investigational Phase 4 77337-73-6, 77337-76-9 71158
35
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
36
Metamfetamine Approved, Illicit, Withdrawn Phase 4 537-46-2 10836
37
Iloperidone Approved Phase 4 133454-47-4 71360
38
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
39
Losartan Approved Phase 4 114798-26-4 3961
40
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
41
Zolpidem Approved Phase 4 82626-48-0 5732
42
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
43
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
46
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
47
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
48
Donepezil Approved Phase 4 120014-06-4 3152
49
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
50
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101

Interventional clinical trials:

(show top 50) (show all 4779)
# Name Status NCT ID Phase Drugs
1 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
2 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
3 Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder Unknown status NCT02752542 Phase 4 Pharmacotherapy
4 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
5 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
6 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
7 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
8 Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR) Unknown status NCT02711215 Phase 4 Citalopram;Escitalopram (Mirtazapine/Duloxetine/Venlafaxine);Placebo
9 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
10 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
11 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
12 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
13 Ketamine Enhancement of rTMS for Refractory Depression Unknown status NCT04352621 Phase 4 intranasal ketamine
14 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
15 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Unknown status NCT03881449 Phase 4
16 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
17 A Prospective Post Marketing Surveillance Study Study for the Evaluation of the Safety and Efficacy of the Predictix Antidepressant (PAD) Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder Unknown status NCT04138290 Phase 4
18 Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy Unknown status NCT03187093 Phase 4 Vortioxetine;Escitalopram
19 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
20 Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Unknown status NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
21 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
22 Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial Unknown status NCT03666494 Phase 4 Ketamine Hydrochloride;Propofol;Fentanyl
23 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
24 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
25 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
26 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
27 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
28 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
29 Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
30 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
31 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Bupropion;Trazodone
32 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
33 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
34 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
35 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
36 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
37 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
38 A Prospective, Single-Blinded, Randomized, Multicentre Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Subjects With a Primary Diagnosis of a Depressive Disorder Unknown status NCT04620499 Phase 4
39 Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT04589143 Phase 4 Agomelatine;Placebos
40 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
41 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
42 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
43 Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression Unknown status NCT04234776 Phase 4 Ketamine
44 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
45 Objective to Evaluate the Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Depressive Episode: a Multicenter Open Randomized Controlled Clinical Trial Unknown status NCT04826510 Phase 4 Perospirone hydrochloride tablets;Lithium carbonate + perospirone hydrochloride;Lithium Carbonate Pill
46 Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Unknown status NCT03491696 Phase 4 Metyrapone
47 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
48 The Assessment of Osteoporosis Treatment in Post-menopausal Women Unknown status NCT03006003 Phase 4 Raloxifene;Alendronate
49 Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression Unknown status NCT03328052 Phase 4
50 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate

Search NIH Clinical Center for Endogenous Depression

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depressive disorder

Genetic Tests for Endogenous Depression

Anatomical Context for Endogenous Depression

Organs/tissues related to Endogenous Depression:

MalaCards : Brain, Prefrontal Cortex, Cortex, Pituitary, Temporal Lobe, Heart, Cingulate Cortex

Publications for Endogenous Depression

Articles related to Endogenous Depression:

(show top 50) (show all 7085)
# Title Authors PMID Year
1
Upregulation of serotonin transporter by alcohol in human dendritic cells: possible implication in neuroimmune deregulation. 53 62
19572987 2009
2
Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. 53 62
15148564 2004
3
Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. 53 62
12960610 2003
4
Relationship between cortisol and serotonin metabolites and transporters in alcoholism [correction of alcolholism]. 53 62
12163982 2002
5
Different effects of pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in endogenous depression and subclinical thyrotoxicosis. 53 62
9440477 1998
6
Suicide: a four-pathway clinical-biochemical model. 53 62
9616805 1997
7
Beta-lipotropin-beta-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Preliminary studies. 53 62
2139563 1990
8
Neuroendocrine aspects of primary endogenous depression. X: Serum growth hormone measures in patients and matched control subjects. 53 62
2111183 1990
9
Whole blood mitochondrial DNA copy number in depression and response to electroconvulsive therapy. 62
36216200 2023
10
Convergent and divergent cognitive impairment of unipolar and bipolar depression: A magnetoencephalography resting-state study. 62
36181913 2023
11
Recent advances in sleep and depression. 62
36449730 2023
12
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. 62
35975555 2023
13
The centrality of working memory networks in differentiating bipolar type I depression from unipolar depression: A task-fMRI study. 62
35244484 2023
14
Circuit-wide proteomics profiling reveals brain region-specific protein signatures in the male WKY rats with endogenous depression. 62
36162674 2023
15
Heterotopic 4T1 breast cancer transplantation induces hippocampal inflammation and depressive-like behaviors in mice. 62
35947291 2022
16
A broken circadian clock: The emerging neuro-immune link connecting depression to cancer. 62
36281466 2022
17
Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson's disease patients. 62
36325427 2022
18
Electroconvulsive Therapy for Unipolar Depression in Older Adults: Overall Outcomes and Clinical Trajectories of Nonresponders. 62
35462391 2022
19
Astrocytes and major depression: The purinergic avenue. 62
36122663 2022
20
The association of exposure to air pollution and depression in women; a cross-sectional study of a middle-income country. 62
36075476 2022
21
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. 62
36128684 2022
22
Associations between children's diagnosed mental disorders and educational achievements in Sweden. 62
35416111 2022
23
Mid- and Late-Life Physical Activity and Neuropsychiatric Symptoms in Dementia-Free Older Adults: Mayo Clinic Study of Aging. 62
36464975 2022
24
Treatment patterns and healthcare utilization of patients with treatment-resistant depression estimated using health insurance database: A population-based study from Taiwan. 62
36096374 2022
25
Early-Onset Type 2 Diabetes and Mood, Anxiety, and Stress-Related Disorders: A Genetically Informative Register-Based Cohort Study. 62
36251507 2022
26
[Multidimensional and computational theory of mood]. 62
35987716 2022
27
A longitudinal study of restless legs symptoms among patients with depression. 62
35191781 2022
28
Effects of emotional contexts on respiratory attention task performance. 62
36368617 2022
29
The use of electroconvulsive therapy (ECT) en bloc in Denmark: a nationwide register-based study. 62
36344233 2022
30
Neurovascular alterations in bipolar disorder: A review of perfusion weighted magnetic resonance imaging studies. 62
35940377 2022
31
Effectiveness of social support-based interventions in preventing depression in people without clinical depression: A systematic review and meta-analysis of randomized controlled trials. 62
36419332 2022
32
The Emotion-Regulation Benefits of Implicit Reappraisal in Clinical Depression: Behavioral and Electrophysiological Evidence. 62
36355339 2022
33
Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study. 62
36331516 2022
34
Association Between Polygenic Risk Scores and Outcome of ECT. 62
36069021 2022
35
The sociodemographic characteristics and clinical features of the late-life depression patients: results from the Beijing Anding Hospital mental health big data platform. 62
36324116 2022
36
Depression in healthcare workers: Results from the nationwide AMADEUS survey. 62
35952535 2022
37
Mental health and behavioural problems in adolescents conceived after ART. 62
36166695 2022
38
[Feasibility, Practicability, and Acceptance of Outpatient Psychotherapy for Home-living Older Adults with Depression in Need of Care in Germany]. 62
36417929 2022
39
Effects of Physical Activity Interventions in the Elderly with Anxiety, Depression, and Low Social Support: A Clinical Multicentre Randomised Trial. 62
36360543 2022
40
Affective working memory in depression. 62
36441997 2022
41
Reduced neural responses to reward reflect anhedonia and inattention: an ERP study. 62
36261598 2022
42
Pain, Anxiety, and Depression in Patients Undergoing Chronic Hemodialysis Treatment: A Multicentre Cohort Study. 62
35466067 2022
43
Exploring antiretroviral therapy adherence, competing needs, and viral suppression among people living with HIV and food insecurity in the Dominican Republic. 62
34581230 2022
44
The importance for wellbeing of having views of nature from and in the home during the COVID-19 pandemic. Results from the GreenCOVID study. 62
35991355 2022
45
A systematic review, meta-analysis, and meta-regression of patient education for secondary prevention in patients with coronary heart disease: impact on psychological outcomes. 62
35134883 2022
46
Navigating the Storm to Recovery through the Pictorial Representations of Persons in the Recovery Phase from Unipolar Depression. 62
36294007 2022
47
Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression. 62
36291336 2022
48
Depression in primary care and the role of evidence-based guidelines: cross-sectional data from primary care physicians in Germany. 62
36280876 2022
49
Working memory updating in individuals with bipolar and unipolar depression: fMRI study. 62
36220840 2022
50
Adapted Behavioural Activation for Bipolar Depression: A Randomised Multiple Baseline Case Series. 62
36291340 2022

Variations for Endogenous Depression

Expression for Endogenous Depression

Search GEO for disease gene expression data for Endogenous Depression.

Pathways for Endogenous Depression

Pathways related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 TRH POMC OXTR OXT HTR2A HTR1A
2 13.38 TRH TPH1 POMC OXTR OXT NR3C1
3
Show member pathways
13.19 TRH POMC OXTR OXT HTR2A HTR1A
4 11.6 POMC NR3C1 IL6
5 11.45 BDNF GNRH1 OXT POMC
6 11.43 TPH1 SLC6A4 NR3C1 MAOA IL6 HTR2A
7
Show member pathways
11.26 TPH1 MAOA COMT
8
Show member pathways
11.09 TRH POMC CRP
9
Show member pathways
11.09 POMC HTR2A HTR1A CRH
10
Show member pathways
10.98 SLC6A4 MAOA COMT
11
Show member pathways
10.92 SLC6A4 MAOA HTR1A COMT
12 10.8 TPH1 SLC6A4 MAOA HTR2A HTR1A
13 10.67 MAOA COMT
14
Show member pathways
10.59 OXTR OXT
15 10.36 POMC CRH
16 10.19 MAOA COMT

GO Terms for Endogenous Depression

Biological processes related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 BDNF CRH GNRH1 HTR1A HTR2A IL6
2 eating behavior GO:0042755 9.91 TRH OXTR OXT
3 serotonin receptor signaling pathway GO:0007210 9.81 HTR2A HTR1A
4 negative regulation of gastric acid secretion GO:0060455 9.8 OXTR OXT
5 positive regulation of penile erection GO:0060406 9.78 OXTR OXT
6 positive regulation of norepinephrine secretion GO:0010701 9.76 OXTR OXT
7 maternal behavior GO:0042711 9.73 OXTR OXT NR3C1
8 response to steroid hormone GO:0048545 9.71 OXTR OXT GNRH1
9 sleep GO:0030431 9.63 OXTR OXT HTR2A
10 behavior GO:0007610 9.52 HTR2A HTR1A
11 sperm ejaculation GO:0042713 9.43 SLC6A4 OXTR OXT
12 regulation of digestive system process GO:0044058 9.32 OXTR OXT
13 memory GO:0007613 9.32 SLC6A4 OXTR OXT HTR2A BDNF

Molecular functions related to Endogenous Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.43 SLC6A4 HTR2A HTR1A
2 hormone activity GO:0005179 9.23 TRH POMC OXT GNRH1 CRH

Sources for Endogenous Depression

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....